YAP1 and psoriasis: For instance, the selective YAP antagonist VP has shown promise in inhibiting keratinocyte proliferation and inflammatory factor production in IMQ-induced psoriasis models, suggesting that targeting YAP could effectively mitigate the pathogenesis of this disease and prompting clinical trials to evaluate the efficacy of YAP inhibitors in psoriasis patients (4).